SmallCap BIOTECH Report <> STEM CELL <> CRYOGENICS <> STEM CELL <> INVESTING IN EMERGING BIOTECH STOCKS :: COMPANY SPOTLIGHT ::. Bio-Matrix Scientific Group Inc. Driving $75 billion dollar a year Biotechnology and Medical Device industries is the demand for new products that improve patient safety, decrease healthcare cost, and most importantly enhance human life. Symbol: BMXP Trading Price: $0.94 About Bio-Matrix Scientific Group Inc.: Bio-Matrix Scientific Group Inc. is a San Diego based development stage company in the business of medical devices and monitoring systems research, development and commercialization. Bio-Matrix Scientific Group Inc. is aligning itself with partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems. Its polymer coating on medical devices will ensure that cell transference is done with minimal damage to cells. This should lead to better yields in stem cell extraction, along with better outcomes for patients in tissue management procedures. Recent News: A spokesperson for the Company said that its Board of Directors plans to spin-off 6,035,501 shares of the common stock of Frezer, Inc., a wholly owned subsidiary of Bio-Matrix Scientific Group, to BMXP shareholders of record as of May 31, 2005. This represents one share of Frezer, Inc. for every one share of Bio-Matrix Scientific Group Inc. (Pink Sheets:BMXP) owned post reverse split. "Ground floor" Company Enters Production Phase Bio-Matrix Scientific Group Inc., announced that Collective Technologies will manufacture Bio-Matrix's first set of Stem Cell Devices. The Company anticipates having this set of instruments sometime within the next two weeks. BMXP also recently finalized applications for 3 new devices. This is the first step towards full production of these devices. This first set of devices will be used for its 510(k) testing, trade shows and presentations to Physicians and Researchers. "Collective Technologies enables us to manufacture products in the most efficient and cost-effective way possible," noted Brian Pockett, Managing Director and COO of Bio-Matrix Scientific. "We have been impressed by Collective Technologies' quality record, responsiveness and flexibility - all of which are critical to our production objectives." Bio-Matrix sees this event as nearing a point at which the Company "green-lights" full production of its stem cell and tissue management instruments. "REAL DEAL" MANAGEMENT Philip Watts, Ph.D., the Company's Director of Research and Development, highly recognized in his field. James L. Lambert, Ph.D., as its Bio-Instrument Scientific Advisor. Dr. Lambert specializes in the development of next generation bio-instrumentation for use in medical research. Dr. Lambert has been with the Jet Propulsion Laboratory for 17 years, and for the last five years he has served as the Technical Group Supervisor of the Intelligent Instrument and Systems Technology Group. Dr. Lambert leads a multidisciplinary group whose members have advanced degrees in chemistry, biology, electrical engineering, and computer science. The charter of the group is to develop advanced in situ instruments and sensors for NASA and other agencies. Geoffrey O'Neill, Ph.D. President of the Company. Dr. O'Neill most recently served as Director of Stem Cell Laboratories and Scientific Research for Cryo-Cell International Inc. (OTC: CCEL). Cryo-Cell International represents themselves as the world's largest U-Cord stem cell banking firm. "The appointment of Dr. O'Neill as President of Bio-Matrix Scientific Group Inc. signals our Company's aggressive growth plans in stem cell research devices, biomedical devices and the continued growth in the development of our Stem Cell Cryogenic Banks," said Brian Pockett, Managing Director and COO of Bio-Matrix Scientific PRODUCT DEVELOPMENT Stem Cell Cryogenics Instrumentation for Stem Cell Research and Tissue Management Non-Invasive Bio-Systems Monitoring and Measuring Devices Niche Medical Device Instrumentation The Company has recently filed a provisional patent application with the U. S. Patent Office. It anticipates numerous utility patents will result from this filing. Investment Prosective: Bio-Matrix has a four pronged revenue strategy each with a different trajectory and different inflection points. The company is spreading its risk over different operating segments with varying investment requirement and levels of risk. Larger companies in the medical device industry are aggressive and smaller companies are always takeover targets. Potential of BMXP: The market size of the segments it has chosen to operate in is huge. The tissue management instruments market size alone is $860 million. A provisional patent application has already been filed and more are in the pipeline. IMPORTANT DISCLAIMER: Information within this email contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, goals, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as: "projects", "foresee", "expects", "estimates," "believes," "understands" "will", "anticipates," or that by statements indicating certain actions "may," "could," or "might" occur. All information provided within this email pertaining to investing, stocks,securities must be understood as information provided and not investment advice. Emerging Equity Alert advises all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this email. None of the material within this report shall be construed as any kind of investment advice. In compliance with Section 1 we have been compensated thirty thousand dollars for the dissemination of this profile.. Be aware of an inherent conflict of interest resulting from such holdings due to our intent to profit from the liquidation of these shares. Shares may be sold at any time, even after positive statements have been made regarding the above company.